pS425/pS429-VPAC2 (IHC grade phospho-VIP Receptor 2 Antibody)

NEW

Preview: Immunohistochemical identification of Serine 425/Serine429 phosphorylation of VPAC2 Receptor in mouse brain suprachiasmatic nucleus.

Preview: Agonist-induced Serine425/Serine429 phosphorylation of VPAC2 Receptor.

Immunohistochemical identification of Serine 425/Serine429 phosphorylation of VPAC2 Receptor in mouse brain suprachiasmatic nucleus.

Agonist-induced Serine425/Serine429 phosphorylation of VPAC2 Receptor.

$ 500.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

Order number: 7TM0372C-IC
Content: 300 µl
Host: Rabbit

Serine425/Serine429 (S425/S429) is a major phosphorylation site of the VPAC2 receptor.... more

Close menu

Serine425/Serine429 (S425/S429) is a major phosphorylation site of the VPAC2 receptor. The pS425/pS429-VPAC2 antibody detects phosphorylation in response to high-efficacy agonists. S425/S429 phosphorylation is a key regulator of VPAC2 desensitization, β-arrestin recruitment and internalization.

Available downloads:

Alternative Names VPAC2, VIP Receptor 2, Vasoactive Intestinal Peptide... more

Close menu

Alternative Names	VPAC2, VIP Receptor 2, Vasoactive Intestinal Peptide Receptor 2
IUPHAR Target ID	372
UniProt ID	P41587 (human)
Western Blot (WB)	1:1000
Immunohistochemistry (IHC)	1:100
Species Reactivity	Human
Host / Isotype	Rabbit / IgG
Class	Polyclonal
Immunogen	A synthetic phosphopeptide derived from human VPAC2 around the phosphorylation site Ser425/Ser429.
Form	Liquid
Purification	Antigen affinity chromatography
Storage buffer	Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions	short-term 4°C, long-term -20°C

Figure 1. Immunohistochemical identification of Serine 425/Serine429 phosphorylation of VPAC2... more

Close menu

Figure 1. Immunohistochemical identification of Serine 425/Serine429 phosphorylation of VPAC2 Receptor in mouse brain suprachiasmatic nucleus. Sections were dewaxed, microwaved in citric acid, and incubated with anti-pS425/pS429-VPAC2 antibody (7TM0372C-IC) or non-phospho anti-VPAC2 antibody (7TM0372N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution.Color was developed by incubation in 3-amino-9-ethylcarbazole (AEC), and sections were counterstained with hematoxylin.

Figure 2. Agonist-induced Serine425/Serine429 phosphorylation of VPAC2 Receptor. Upper panel, HEK293 cells stably expressing the VPAC2-Receptor (VPAC2) were either not exposed or exposed to 1 µM of specific VPAC-Receptor agonist PACAP-27 for 30 minutes. Cells were lysed and immunoblotted with the anti-pS425/pS429-VPAC2 antibody (7TM0372C-IC) at a dilution of 1:1000. Lower panel, blot was stripped and reprobed with the phosphorylation-independent anti-VPAC2 antibody (7TM0372N) at a dilution of 1:1000 to confirm equal loading of the gel.